Int J Radiat Oncol Biol Phys 2023 Mar 01
Alleviating morbidity from locally advanced breast cancer using a practical and short radiotherapy regime: Results of the HYPORT palliative studies.
Abstract
Purpose
Locally advanced breast cancers lead to debilitating local symptoms. Treatment of these women encountered commonly in less resourced countries, is not backed by strong evidence. We formulated the XXX and XXX B phase I/II studies to evaluate the safety and efficacy of hypofractionated palliative breast radiotherapy.
Material & methods
Two studies (35Gy/ 10 fractions -XXX) and (26Gy to breast/ 32Gy tumour boost in 5 fractions -XXX B) were designed with increasing hypofractionation to save overall treatment time from 10 to 5 days. We report the acute toxicity, symptomatic, metabolic response and quality of life (QOL) changes following radiotherapy.
Results
Fifty eight patients, majority pretreated with systemic therapy, completed the treatment. No grade 3 toxicity was reported. Response assessment at 3 months showed improvement in ulceration (58% versus 22%, p=0.013), bleeding (22% versus 0%, p=0.074) within the XXX study. Similarly, in XXX B study, ulceration (64% and 39%, p=0.2), fungating (26% and 0%, p=0.041), bleeding (26% and 4.3%, p=0.074), discharge (57% and 8.7%, p=0.003) was reduced . Metabolic response was noted in 90% and 83% patients respectively in the two studies. Improvement in the QOL scores were evident in both studies. Only 10% patients' relapsed locally within one year.
Conclusion
Palliative ultra hypofractionated radiotherapy to the breast is well tolerated, effective and results in a durable response with improved QOL. This could be considered as a standard for locoregional symptom control.
Related Questions
How do you manage a symptomatic primary breast tumor in a patient with metastatic disease?
It’s much harder to treat patients palliatively than to cure. The art of palliation generally requires weighing the acute and subacute toxicities of alternative treatments much more heavily and chronic toxicities less than we do for potentially curative care. It also requires assessing whether patie...
For insurance, how do you justify medical necessity for IMRT to the pancreas in the preoperative, unresectable, and post-operative settings?
I work in prior auth. In all three cases, IMRT would be auto-approved where I work. Other third parties are restrictive about this and it is unclear to me why. In any case, though it is burdensome, if I was in a region that was restrictive, I would do a comparison plan right off the bat. As annoying...
When offering palliative radiation for breast cancer, what dose/fractionation do you prefer and in what subset of patients do you believe derive the most benefit?
More recently after FAST-Forward, use 26 Gy in 5 for palliation as shorter and reasonable dose to palliate pain, bleeding, and drainage.
How do you explain the risks and benefits of palliative radiation therapy to patients with fungating breast masses?
The value of palliative RT in these patients is to dry up oozing and bleeding and RT is very effective in achieving that goal. I have had success in these patients almost all the time and my usual dose is 30-39 Gy in 10-13 fractions.This study gives a prospective dataset for fractionation and pallia...